Alonso Krangle LLP, a national law firm focused on fighting for the rights of victims of serious drug injuries, are warning today about the findings of a new study indicating that women who use NuvaRing
Melville, NY (PRWEB) May 14, 2012
According to a New Study in the British Medical Journal NuvaRing May Double the Risk for Serious Blood Clots, including Deep Vein Thrombosis and Pulmonary Embolism, Compared to Birth Control Pills
Alonso Krangle LLP, a national law firm focused on fighting for the rights of victims of serious drug injuries, are warning today about the findings of a new study indicating that women who use NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) may face an increased risk for serious blood clots, including life-threatening deep vein thrombosis and pulmonary embolism. The study, which compared the risk of blood clots between women who used non-oral hormonal forms of birth control, such as NuvaRing, to those taking birth control pills, was published May 10, 2012 in the online edition of the British Medical Journal [bmj.com/content/344/bmj.e2990]
Alonso Krangle is currently offering free Nuvaring lawsuit consultations to victims of NuvaRing side effects, including:
- Blood clots
- Deep vein thrombosis
- Pulmonary embolism
- Heart attacks
- Wrongful death
To discuss a potential claim with one of the experienced and compassionate NuvaRing side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com
The British Medical Journal study analyzed information on more than 1.6 million Danish women between ages 15 and 49 who were followed from 2001 to 2010. During that time, there were more than 3,400 diagnoses of venous thrombosis, a class of serious blood clots that includes pulmonary embolism and deep vein thrombosis. Among other things, the analysis found that women who used a vaginal ring – NuvaRing – had a 6.5 times higher risk of experiencing a serious blood clot compared to women who did not use any form of hormonal birth control. For women using birth control pills containing the hormone levonorgestrel, the risk for a blood clot was only three times higher compared to those who did not use a hormonal birth control method. There was no reduction in blood clot risk associated with long-term use of a vaginal ring, the study authors said.
Serious blood clots, including deep vein thrombosis and pulmonary embolism, can lead to heart attacks, strokes and even sudden death. Considering the potentially life-threatening NuvaRing side effects seen in this study, the attorneys of Alonso Krangle urge young women who are currently using NuvaRing for contraception to discuss its risks and benefits with their doctors.
About NuvaRing Marketed by Merck & Co.’s Organon subsidiary, NuvaRing was introduced to the U.S. marketplace in 2001. NuvaRing is a small flexible ring that is designed to be inserted into the vagina once a month. It is kept in place for three weeks, and prevents pregnancy by releasing controlled amounts of etonogestrel, a synthetic generation progestin, and the estrogen, ethinyl estradiol into the bloodstream.
Etonogestrel is a form of desogestrel, a third-generation progestin. In February 2007, the consumer advocacy group Public Citizen petitioned the U.S. Food & Drug Administration (FDA) to ban oral birth control pills that contain desogestrel, citing studies which indicated they could double the risk of blood clots compared to second generation oral contraceptives. Last October, the FDA published a study comparing different methods of hormonal birth control that found NuvaRing raised the risk of blood clots, including deep vein thrombosis and pulmonary embolism, by 56% when compared to older birth control pills. The FDA study noted that combined hormonal contraceptives, including the etonogestrel/ethinyl estradiol vaginal ring, “potentially result in higher sustained exposure to estrogen and hence, increased thromboembolic risk.” [citizen.org/notmypill; fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf]
According to Merck & Co.’s 10-K earnings statement report for the fiscal year 2011, the company currently faces more than 950 NuvaRing lawsuits alleging the hormonal birth control device caused serious injuries, including blood clots, deep vein thrombosis, pulmonary embolism, heart attacks, strokes, or wrongful death. According to the report, dated February 28, 2012, 820 lawsuits are or will be pending in a multidistrict litigation before Rodney W. Sippel of the U.S. District Court, Eastern District of Missouri (MDL No. 1964). Roughly 125 additional lawsuits are pending in a Mass Tort proceeding in the Bergen County Superior Court of New Jersey, according to the report (Docket No. BER-L-3081-09). [merck.com/investors/financials/form-10-k-2011.pdf]
There is still time for young women who may have been injured by NuvaRing, or their families, to file personal injury lawsuits seeking compensation for medical bills, pain and suffering, emotional distress and other damages. To discuss a potential claim with one of the experienced and compassionate NuvaRing side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
About Alonso Krangle LLP Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical malpractice, whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and plans to open additional locations in New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
Alonso Krangle LLP
445 Broad Hollow Road
Suite 205 Melville,
New York 11747